Moleculin Biotech, Inc. (MBRX) Financials

MBRX

FY2025 annual

Revenue $0 YoY not available

Net Income $33.6M +28.8% YoY

Free Cash Flow -$22.7M +4.8% YoY

Operating Cash Flow -$22.7M +4.7% YoY

Market Cap $9.7M as of Oct 5, 2026

Price / Sales n/m revenue is not positive, FY2025

Price / Earnings 0.3x on $33.6M net income, FY2025

Price / Book 0.8x on $11.6M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MBRX SEC filings page.

Moleculin Biotech, Inc. (MBRX) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MBRX FY2025 2026-10-03

Moleculin remains a cash-consuming development business: reported earnings are positive, but operations depend on external financing.

The unusual pattern is that FY2025's $33.6M net income coexisted with a $25.1M operating loss. Across FY2023-FY2025, positive net income did not translate into operating cash, so reported earnings are being shaped by items outside recurring operations.

The cost structure is development-focused: FY2025 research and development was $15.9M. That investment was lower than the prior year, yet operating cash outflow remained $22.7M, showing that research is only part of the cash requirement.

FY2025 financing provided $27.3M against $22.7M of operating cash outflow, making outside capital the immediate source of net cash support rather than operations. The current ratio was 1.4x, up from 1.0x in FY2024, indicating improved short-term coverage driven alongside that financing.

Financial Health Signals

Financial health score not available

Moleculin Biotech, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-15.81

Moleculin Biotech, Inc. scores -15.81, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($9.7M) relative to total liabilities ($7.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/7

Moleculin Biotech, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

$0.68used

For every $1 of reported earnings, Moleculin Biotech, Inc. used $0.68 of operating cash (-$22.7M OCF vs $33.6M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Moleculin Biotech, Inc. generated $0 in revenue in Q2 2026.

EBITDA

-$7.6M

YoY-32.7%

QoQ+4.0%

Moleculin Biotech, Inc.'s EBITDA was -$7.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 32.7% from the same quarter a year earlier. Against the prior quarter it is up 4.0%.

Net Income

-$7.6M

YoY+57.1%

QoQ+40.6%

Moleculin Biotech, Inc. reported -$7.6M in net income in Q2 2026. This represents an increase of 57.1% from the same quarter a year earlier. Against the prior quarter it is up 40.6%.

EPS (Diluted)

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$7.3M

YoY-3.9%

QoQ-29.6%

5Y CAGR-38.0%

10Y CAGR0.0%

Moleculin Biotech, Inc. held $7.3M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

19M

YoY-35.7%

5Y CAGR-7.4%

10Y CAGR+5.6%

Moleculin Biotech, Inc. had 19M shares outstanding in Q2 2026. This represents a decrease of 35.7% from the same quarter a year earlier.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-65.9%

QoQ+18.7pp

Moleculin Biotech, Inc.'s ROE was -65.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is up 18.7 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$5.5M

YoY+51.4%

QoQ+1.3%

Moleculin Biotech, Inc. invested $5.5M in research and development in Q2 2026. This represents an increase of 51.4% from the same quarter a year earlier. Against the prior quarter it is up 1.3%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

MBRX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MBRX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Revenue	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A
R&D Expenses	N/A	$15.9M-10.4%	$17.7M-9.0%	$19.5M+2.7%	$19.0M+31.6%	$14.4M+13.0%	$12.8M+15.8%	$11.0M+13.2%	$9.7M+114.0%	$4.5M+203.8%	$1.5M	N/A
SG&A Expenses	N/A	$9.1M+3.8%	$8.8M-12.3%	$10.0M-13.2%	$11.5M+37.6%	$8.4M+23.6%	$6.8M+7.5%	$6.3M+20.7%	$5.2M+27.8%	$4.1M+71.8%	$2.4M	N/A
Operating Income	N/A	-$25.1M+5.8%	-$26.6M+10.1%	-$29.6M+3.3%	-$30.6M-33.4%	-$23.0M-16.3%	-$19.7M-12.7%	-$17.5M-16.6%	-$15.0M-73.6%	-$8.7M-122.8%	-$3.9M	N/A
EBITDA	N/A	-$25.0M+5.7%	-$26.5M+10.1%	-$29.5M+3.3%	-$30.5M-33.8%	-$22.8M-16.7%	-$19.5M-12.8%	-$17.3M-15.8%	-$15.0M-73.2%	-$8.6M-122.7%	-$3.9M	N/A
Interest Expense	N/A	N/A	N/A	N/A	$240K-21.6%	$306K+2253.8%	$13K0.0%	$13K+225.0%	$4K	$0-100.0%	$43K	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0+100.0%	-$229K	$0	$0	$0	$0
Net Income	N/A	$33.6M+28.8%	$26.0M-12.5%	$29.8M+202.6%	-$29.0M-82.6%	-$15.9M+8.4%	-$17.4M-31.4%	-$13.2M-11.2%	-$11.9M-21.1%	-$9.8M-149.7%	-$3.9M	N/A
EPS (Basic)	N/A	-$28.42+85.0%	-$189.14-1155.1%	-$15.07+1.0%	-$15.22-2479.7%	-$0.59	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$0	$0	N/A	$0	$0	$0	N/A	$0
R&D Expenses	$5.5M+51.4%	$5.4M+56.6%	N/A	$3.7M-24.2%	$3.6M-12.0%	$3.4M-19.2%	N/A	$4.9M+50.4%
SG&A Expenses	$2.1M+0.6%	$2.5M+0.4%	N/A	$2.1M-1.2%	$2.1M+1.3%	$2.5M+3.5%	N/A	$2.2M-17.6%
Operating Income	-$7.6M-32.2%	-$7.9M-32.5%	N/A	-$5.9M+17.2%	-$5.7M+7.5%	-$5.9M+11.0%	N/A	-$7.1M-20.0%
EBITDA	-$7.6M-32.7%	-$7.9M-33.1%	N/A	-$5.9M+17.2%	-$5.7M+7.5%	-$5.9M+11.0%	N/A	-$7.1M-20.1%
Interest Expense	$78K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	N/A	$0	$0	$0	N/A	$0
Net Income	-$7.6M+57.1%	-$12.8M-117.6%	N/A	-$25.4M-261.6%	-$17.8M-196.1%	-$5.9M+8.1%	N/A	-$7.0M-25.2%
EPS (Basic)	-$1.40+95.1%	-$3.54+77.6%	-$26.06+85.7%	-$0.68+64.0%	-$28.68-1110.1%	-$15.80-505.4%	-$182.45-1166.1%	-$1.89+33.0%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EPS (Diluted), Diluted Shares (Avg).

MBRX Balance Sheet

MBRX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Total Assets	$22.1M+30.7%	$16.9M-55.7%	$38.2M-33.4%	$57.4M-31.7%	$84.1M+189.7%	$29.0M+15.0%	$25.2M+28.8%	$19.6M+0.5%	$19.5M+18.8%	$16.4M+58256.8%	$28K
Current Assets	$9.7M+86.5%	$5.2M-80.2%	$26.3M-42.4%	$45.6M-37.1%	$72.5M+321.5%	$17.2M+27.5%	$13.5M+69.1%	$8.0M-4.0%	$8.3M+59.0%	$5.2M+18489.6%	$28K
Cash & Equivalents	$8.9M+107.5%	$4.3M-81.8%	$23.6M-45.4%	$43.1M-39.1%	$70.9M+367.3%	$15.2M+41.3%	$10.7M+50.5%	$7.1M-7.5%	$7.7M+54.1%	$5.0M+17782.1%	$28K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	$1K-98.2%	$56K	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$7.1M+24.5%	$5.7M-52.9%	$12.1M+132.2%	$5.2M+2.6%	$5.1M-54.8%	$11.3M+16.6%	$9.7M+81.9%	$5.3M+124.7%	$2.4M+65.0%	$1.4M+85.4%	$773K
Current Liabilities	$6.9M+27.9%	$5.4M-21.4%	$6.8M+41.4%	$4.8M+33.0%	$3.6M+24.0%	$2.9M-18.2%	$3.6M-7.9%	$3.9M+75.1%	$2.2M+64.7%	$1.3M+74.0%	$773K
Non-Current Liabilities	$266K-25.7%	$358K-93.3%	$5.3M+1193.4%	$412K-72.1%	$1.5M-82.3%	$8.4M+37.0%	$6.1M+324.7%	$1.4M+856.7%	$150K+70.5%	$88K	$0
Total Equity	$15.0M+33.9%	$11.2M-63.8%	$30.9M-40.7%	$52.2M-33.9%	$79.0M+344.8%	$17.8M+14.1%	$15.6M+9.1%	$14.3M-16.6%	$17.1M+14.4%	$15.0M+2108.1%	-$745K
Retained Earnings	-$206.0M-19.5%	-$172.4M-31.0%	-$131.6M-29.2%	-$101.8M-39.9%	-$72.8M-27.9%	-$56.9M-43.9%	-$39.6M-50.1%	-$26.4M-82.0%	-$14.5M-209.7%	-$4.7M-524.7%	-$748K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$21.1M-2.3%	$23.4M+11.2%	$22.1M+30.7%	$20.4M-13.0%	$21.6M-15.6%	$21.0M-31.9%	$16.9M-55.7%	$23.4M-40.8%
Current Assets	$8.7M-3.9%	$11.0M+17.4%	$9.7M+86.5%	$7.9M-32.1%	$9.1M-33.9%	$9.3M-50.7%	$5.2M-80.2%	$11.6M-58.0%
Cash & Equivalents	$7.3M-3.9%	$10.3M+33.7%	$8.9M+107.5%	$6.7M-28.7%	$7.6M-30.3%	$7.7M-54.1%	$4.3M-81.8%	$9.4M-61.7%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$9.5M-62.3%	$8.2M+13.3%	$7.1M+24.5%	$47.3M+690.1%	$25.2M+219.9%	$7.2M-22.0%	$5.7M-52.9%	$6.0M+36.4%
Current Liabilities	$9.3M+17.7%	$8.0M+15.5%	$6.9M+27.9%	$5.7M+1.6%	$7.9M+37.7%	$6.9M+27.5%	$5.4M-21.4%	$5.6M+43.9%
Non-Current Liabilities	$187K-98.9%	$218K-33.1%	$266K-25.7%	$41.6M+10564.4%	$17.3M+712.9%	$326K-91.5%	$358K-93.3%	$390K-21.5%
Total Equity	$11.6M+323307.8%	$15.2M+10.1%	$15.0M+33.9%	-$26.9M-254.6%	-$4K-100.0%	$13.8M-44.8%	$11.2M-63.8%	$17.4M-50.4%
Retained Earnings	-$226.5M-15.5%	-$218.8M-22.7%	-$206.0M-19.5%	-$221.6M-46.3%	-$196.2M-39.2%	-$178.3M-30.6%	-$172.4M-31.0%	-$151.5M-24.8%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

MBRX Cash Flow Statement

MBRX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Operating Cash Flow	-$25.4M	-$22.7M+4.7%	-$23.9M-1.1%	-$23.6M+14.6%	-$27.6M-45.8%	-$19.0M-6.6%	-$17.8M-3.3%	-$17.2M-40.9%	-$12.2M-66.6%	-$7.3M-94.5%	-$3.8M	N/A
Depreciation & Amortization	N/A	$90K-28.6%	$126K-0.8%	$127K-2.3%	$130K-20.7%	$164K-18.0%	$200K+0.5%	$199K+192.6%	$68K+277.8%	$18K+200.0%	$6K	N/A
Stock-Based Compensation	N/A	$1.7M-3.6%	$1.7M-13.0%	$2.0M-12.8%	$2.3M-4.1%	$2.4M+41.3%	$1.7M+9.3%	$1.5M+34.8%	$1.1M+61.2%	$707K+118.2%	$324K	N/A
Capital Expenditures	N/A	$0-100.0%	$13K-89.5%	$124K+85.1%	$67K+252.6%	$19K-94.9%	$376K+623.1%	$52K-87.5%	$417K+1389.3%	$28K+33.3%	$21K	N/A
Free Cash Flow	N/A	-$22.7M+4.8%	-$23.9M-0.7%	-$23.7M+14.4%	-$27.7M-46.1%	-$19.0M-4.5%	-$18.1M-5.2%	-$17.3M-36.7%	-$12.6M-71.7%	-$7.4M-94.2%	-$3.8M	N/A
Investing Cash Flow	$0	$0+100.0%	-$13K+89.5%	-$124K-85.1%	-$67K-252.6%	-$19K+94.9%	-$374K-633.3%	-$51K+87.8%	-$417K-1389.3%	-$28K+76.9%	-$121K	N/A
Financing Cash Flow	$25.1M	$27.3M+488.7%	$4.6M+11.9%	$4.1M+18104.3%	-$23K-100.0%	$74.7M+231.4%	$22.5M+8.1%	$20.9M+73.1%	$12.0M+19.7%	$10.1M+13.5%	$8.9M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$6.7M-19.3%	-$6.1M-33.9%	-$5.4M-5.6%	-$7.2M-18.2%	-$5.6M+6.2%	-$4.6M+32.1%	-$5.1M-3.8%	-$6.1M+19.0%
Depreciation & Amortization	$8K-72.4%	$8K-74.2%	$9K-71.0%	$21K-32.3%	$29K-6.5%	$31K-3.1%	$31K-11.4%	$31K-3.1%
Stock-Based Compensation	$436K+4.6%	$380K-21.6%	N/A	$303K-14.2%	$417K-7.9%	$485K-1.6%	N/A	$353K-28.4%
Capital Expenditures	N/A	N/A	$0	$0	$0-100.0%	$0	$0-100.0%	$0-100.0%
Free Cash Flow	N/A	N/A	-$5.4M-5.6%	-$7.2M-18.2%	-$5.6M+6.4%	-$4.6M+32.1%	-$5.1M-2.1%	-$6.1M+19.3%
Investing Cash Flow	$0	$0	$0	$0	$0+100.0%	$0	$0+100.0%	$0+100.0%
Financing Cash Flow	$3.6M-33.4%	$7.6M-4.8%	$7.5M+748600.0%	$6.4M+36.8%	$5.4M+21792.0%	$8.0M	$1K-100.0%	$4.7M+116575.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

MBRX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MBRX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Return on Equity	223.6%-8.8pp	232.4%+136.2pp	96.3%+151.9pp	-55.6%-35.5pp	-20.1%+77.6pp	-97.7%-12.9pp	-84.8%-1.6pp	-83.2%-25.9pp	-57.3%-31.0pp	-26.2%	N/A
Return on Assets	151.7%-2.2pp	153.9%+76.0pp	77.9%+128.4pp	-50.5%-31.6pp	-18.9%+40.9pp	-59.8%-7.5pp	-52.3%+8.3pp	-60.6%-10.3pp	-50.3%-26.4pp	-23.9%	N/A
Current Ratio	1.41+0.4x	0.97-2.9x	3.86-5.6x	9.46-10.6x	20.02+14.1x	5.89+2.1x	3.78+1.7x	2.06-1.7x	3.75-0.1x	3.88+3.8x	0.04
Debt-to-Equity	0.470.0x	0.51+0.1x	0.39+0.3x	0.100.0x	0.06-0.6x	0.630.0x	0.62+0.2x	0.37+0.2x	0.140.0x	0.10	N/A
Asset Turnover	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.00	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-65.9%	-84.6%-41.8pp	N/A	N/A	N/A	-42.8%-17.1pp	N/A	-40.3%-24.4pp
Return on Assets	-36.2%+46.3pp	-55.0%-26.9pp	N/A	-124.8%-94.8pp	-82.5%-59.0pp	-28.1%-7.3pp	N/A	-30.0%-15.8pp
Current Ratio	0.94-0.2x	1.380.0x	1.41+0.4x	1.39-0.7x	1.15-1.2x	1.35-2.2x	0.97-2.9x	2.08-5.0x
Debt-to-Equity	0.82	0.540.0x	0.470.0x	N/A	N/A	0.52+0.2x	0.51+0.1x	0.34+0.2x
Asset Turnover	0.000.0x	0.000.0x	N/A	0.000.0x	0.000.0x	0.000.0x	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Moleculin Biotech, Inc. MBRX	FY2025	$0	$33.6M	N/A	$9.7M	—
Leap Therapeutics, Inc. LPTX	FY2025	N/A	$5.0M	N/A	$116.1M	—
Mustang Bio, Inc. MBIO	FY2025	N/A	-$1.9M	N/A	$3.6M	—
Intensity Therapeutics, Inc. INTS	FY2025	N/A	-$11.6M	N/A	$11.2M	—
Soligenix, Inc. SNGX	FY2025	N/A	-$11.1M	N/A	$8.0M	—

Where Moleculin Biotech, Inc. Ranks

Frequently Asked Questions

What is Moleculin Biotech, Inc.'s annual revenue?

Moleculin Biotech, Inc. (MBRX) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Moleculin Biotech, Inc. profitable?

Yes, Moleculin Biotech, Inc. (MBRX) reported a net income of $33.6M in fiscal year 2025.

What is Moleculin Biotech, Inc.'s EBITDA?

Moleculin Biotech, Inc. (MBRX) had EBITDA of -$25.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Moleculin Biotech, Inc.'s return on equity (ROE)?

Moleculin Biotech, Inc. (MBRX) has a return on equity of 223.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Moleculin Biotech, Inc.'s free cash flow?

Moleculin Biotech, Inc. (MBRX) recorded an outflow of $22.7M in free cash flow during fiscal year 2025. This represents a 4.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Moleculin Biotech, Inc.'s operating cash flow?

Moleculin Biotech, Inc. (MBRX) recorded an outflow of $22.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Moleculin Biotech, Inc.'s total assets?

Moleculin Biotech, Inc. (MBRX) had $22.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Moleculin Biotech, Inc.'s capital expenditures?

Moleculin Biotech, Inc. (MBRX) reported no capital expenditure during fiscal year 2025.

How much does Moleculin Biotech, Inc. spend on research and development?

Moleculin Biotech, Inc. (MBRX) invested $15.9M in research and development during fiscal year 2025.

How many shares does Moleculin Biotech, Inc. have outstanding?

Moleculin Biotech, Inc. (MBRX) had 5M shares outstanding as of fiscal year 2025.

What is Moleculin Biotech, Inc.'s current ratio?

Moleculin Biotech, Inc. (MBRX) had a current ratio of 1.41 as of fiscal year 2025, which is considered adequate.

What is Moleculin Biotech, Inc.'s debt-to-equity ratio?

Moleculin Biotech, Inc. (MBRX) had a debt-to-equity ratio of 0.47 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Moleculin Biotech, Inc.'s return on assets (ROA)?

Moleculin Biotech, Inc. (MBRX) had a return on assets of 151.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Moleculin Biotech, Inc.'s P/E ratio?

Moleculin Biotech, Inc. (MBRX) trades at 0.3x earnings, its market capitalization divided by net income of $33.6M net income, FY2025. The market capitalization is $9.7M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Moleculin Biotech, Inc.'s price-to-sales ratio?

Moleculin Biotech, Inc. (MBRX) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $9.7M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Moleculin Biotech, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Moleculin Biotech, Inc. (MBRX) held $8.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $22.7M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Moleculin Biotech, Inc.'s Altman Z-Score?

Moleculin Biotech, Inc. (MBRX) has an Altman Z-Score of -15.81, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Moleculin Biotech, Inc.'s Piotroski F-Score?

Moleculin Biotech, Inc. (MBRX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Moleculin Biotech, Inc.'s earnings high quality?

For every $1 of reported earnings, Moleculin Biotech, Inc. (MBRX) used $0.68 of operating cash (-$22.7M OCF vs $33.6M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.